Find here all our blog posts tagged with: AI drug discovery.

Glowing digital data particles representing AI-driven drug discovery converge on a stone archway symbolizing regulatory evidence requirements.

AI Discovers Drugs. It Doesn't Approve Them.

AI drug discovery has drawn billions in investment but zero FDA approvals, and the bottleneck sponsors need to plan for is evidence, not speed.

Glowing molecular structures multiplying rapidly on one side and funneling through a narrow glass bottleneck on the other, symbolizing the gap between AI drug discovery and clinical trial execution.

AI Can Design a Drug. It Still Can't Get One Approved.

Generative AI is accelerating drug candidate design, but no AI-discovered molecule has reached approval because clinical trial execution and its regulatory footing remain unresolved.

Abstract split image contrasting a clear, resolved network pathway with a dense, unresolved tangle of nodes, symbolizing divergent regulatory progress in life sciences AI.

Life Sciences AI Is Moving at Two Different Speeds

Diagnostic AI is clearing FDA review on schedule while AI-native drug discovery still has zero approvals, and the gap is documentation, not science.